Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
Ferrando Díez, Angelica (Institut Germans Trias i Pujol)
Felip, Eudald (Institut Germans Trias i Pujol)
Felip, Enriqueta (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Pous, Anna (Institut Germans Trias i Pujol)
Sirven, Milana Bergamino (Institut Germans Trias i Pujol)
Margelí, Mireia (Institut Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Despite the improvement achieved by the introduction of HER2-targeted therapy, up to 25% of early human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients will relapse. Beyond trastuzumab, other agents approved for early HER2+ BC include the monoclonal antibody pertuzumab, the antibody-drug conjugate (ADC) trastuzumab-emtansine (T- DM1) and the reversible HER2 inhibitor lapatinib. New agents, such as trastuzumab-deruxtecan or tucatinib in combination with capecitabine and trastuzumab, have also shown a significant improvement in the metastatic setting. Other therapeutic strategies to overcome treatment resistance have been explored in HER2+ BC, mainly in HER2+ that also overexpress estrogen receptors (ER+). In ER+ HER2+ patients, target therapies such as phosphoinositide-3-kinase (PI3K) pathway inhibition or cyclin-dependent kinases 4/6 blocking may be effective in controlling downstream of HER2 and many of the cellular pathways associated with resistance to HER2-targeted therapies. Multiple trials have explored these strategies with some promising results, and probably, in the next years conclusive results will succeed. In addition, HER2+ BC is known to be more immunogenic than other BC subgroups, with high variability between tumors. Different immunotherapeutic agents such as HER-2 therapy plus checkpoint inhibitors, or new vaccines approaches have been investi-gated in this setting, with promising but controversial results obtained to date.
Ajuts:	Instituto de Salud Carlos III CM20/00027
Nota:	Conflicts of Interest: AFD declares travel expenses from Roche, MSD and Novartis. EF declares a consulting and advisory role for Novartis; research funding from Pfizer and travel expenses from Lilly, Novartis and Pfizer. AP declares travel expenses from Roche and BMS. MM has participated as an advisor of Lilly, Seagen, Novartis, Pficer, Roche, and Kern; her institution has received re- search funding from Pfizer, Roche, Eisai, Astrazeneca and Kern and travel expenses from Gilead. MB declares no potential conflict of interest.
Nota:	Funding: This research received no external funding. EF is supported by a Rio Hortega grant from the Instituto de Salud Carlos III (ISCIII- CM20/00027).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Cancers, Vol. 14 Núm. 14 (7-2 2022) , p. 3305, ISSN 2072-6694

DOI: 10.3390/cancers14143305
PMID: 35884366

23 p, 904.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats